Latest Content

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

This commentary will appear in the August issue of Evidence-Based Oncology.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Boston heart failure specialists discussed diagnostic gaps, cost barriers to newer therapies, and scalable care models for HFpEF and HFmrEF.

Summer heat may accelerate microplastic exposure, raising concerns about health effects and climate impacts.

GPBCH's podcast series helps employers navigate GLP-1 strategy and oncology care access, pairing data-driven insights with patient literacy tools.